Document:

<PAGE>
                                                               EXHIBIT 10(b)(ii)

                                               PART IX -- ADDITIONAL INFORMATION

18.7     AVAILABLE INFORMATION

National Grid is (and following the Merger, New National Grid Transco will
continue to be) subject to the information requirements of the US Exchange Act
applicable to foreign private issuers having securities registered under section
12 thereof and in accordance therewith, file annual reports and other
information with the SEC. The annual reports and other information filed by
National Grid (and following the Merger, by National Grid Transco) can be
inspected and copied at the public reference rooms maintained by the SEC at
Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549, and at the
regional offices of the SEC located in Chicago, Illinois and New York, New York.
Copies of such material are also available by mail from the public reference
room of the SEC at 450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed
rates. Members of the public may obtain information on the operation of the
public reference rooms by calling the SEC at 800-732-0330 (within the US) or
+1-202-942-8090 (outside the US). In addition, such material may also be
inspected and copied at the offices of the New York Stock Exchange, 20 Broad
Street, New York, New York 10005.

19.      MATERIAL CONTRACTS

19.1     NATIONAL GRID GROUP

19.1.1   Save for the contracts described in section 19.1.2 below, the consent
         and undertaking described in section 19.2.2 below and the contracts
         which have been made available for inspection in the last two years
         described in section 19.1.3 below, no contracts (other than contracts
         entered into in the ordinary course of business) have been entered into
         by any member of National Grid Group: (a) within the two years
         immediately preceding the date of this document which are, or may be,
         material; or (b) which contain any provision under which any member of
         National Grid Group has any obligation or entitlement which is material
         to National Grid Group as at the date of this document.

19.1.2   (a)      An inducement fee agreement dated 22 April 2002 between (1)
                  National Grid and (2) Lattice entered into in connection with
                  the Merger (the "Inducement Fee Agreement"). The Inducement
                  Fee Agreement provides for either party to pay the other a fee
                  of (pound) 60 million if:

                  (i)      an announcement is made during the offer period by a
                           third party indicating an intention to make an offer
                           for, or proposal relating to the change of control
                           of, either party, as a result of which either: (a)
                           the shareholders of such party do not pass the
                           necessary resolutions approving the Merger; or (b)
                           such party terminates discussions with the other
                           party; or

                  (ii)     either party notifies or indicates to the other party
                           that its directors will not unanimously recommend its
                           shareholders to vote in favour of the Merger or the
                           directors of such party do not make such
                           recommendation or withdraw their recommendation or
                           recommend an alternative offer or transaction
                           involving a change of control; or

                  (iii)    either party takes any action or omits to take any
                           action (other than as a consequence of a third party
                           regulatory body failing to approve the Merger or
                           placing unacceptable conditions on the Merger in the
                           reasonable opinion of either party) which is
                           reasonably likely to cause the Merger to not become
                           effective,

                  and in each case the Merger does not become effective in
                  accordance with its terms;

         (b)      a sale and purchase agreement dated as of 13 April 2002 and
                  made by and among North Atlantic Energy Corporation, The
                  United Illuminating Company, Great Bay Power Corporation, NEP,
                  The Connecticut Light and Power Company, Canal Electric
                  Company, Little Bay Power Corporation, New Hampshire Electric
                  Cooperative, Inc., North Atlantic Energy Service Corporation,
                  and FPL Energy Seabrook LLC whereby:

                  (i)      FPL Energy Seabrook LLC agreed to purchase NEP's
                           approximate 9.96 per cent. interest in the Seabrook
                           Nuclear Power Station, together with the interests of
                           the sellers listed above (a total of approximately
                           88.23 per cent. of the interests in Seabrook);

                  (ii)     FPL Energy Seabrook LLC agreed to pay an aggregate of
                           $836.6 million (subject to adjustment) to NEP and the
                           other sellers for the assets acquired under the sale
                           and purchase agreement and NEP's share of such
                           proceeds is estimated with known purchase price
                           adjustments to be approximately $94.1 million;

                  (iii)    FPL Energy Seabrook LLC assumed most of the sellers'
                           obligations as related to the Seabrook Nuclear Power
                           Station, including responsibility for all liabilities
                           and obligations of NEP under contractual obligations
                           relating to the assets, certain liabilities and

                                       227
<PAGE>

                           obligations with respect to the employees employed at
                           the facilities, and responsibility for environmental
                           liabilities at the facilities except for pre-closing
                           violations and off-site disposal of, and
                           responsibility for decommissioning Seabrook;

                  (iv)     FPL Group Capital Inc. agreed to guarantee the FPL
                           Energy Seabrook LLC's payment of the purchase price
                           and provide funding assurance for FPL Energy Seabrook
                           LLC's funding obligations as required by the New
                           Hampshire Nuclear Decommissioning Financing
                           Committee; and

                  (v)      NEP is required under pre-existing agreements to
                           first offer its interests in Seabrook to the
                           non-selling owners on equivalent terms. The
                           non-selling owners have until late June 2002 to
                           notify NEP if they will purchase NEP's interest; and

         (c)      a guarantee and indemnity given to EIB by National Grid dated
                  11 February 2002 under which National Grid guarantees the
                  financial obligations of Energis Polska to EIB in relation to
                  a Euro 125 million loan facility granted to Energis Polska by
                  EIB.

19.1.3   (a)      The consent to the National Grid Scheme and the undertaking to
                  be bound by its terms executed by National Grid in favour of
                  National Grid Holdings One plc and dated 10 December 2001;

         (b)      a sponsor's agreement dated 10 December 2001 between National
                  Grid, National Grid Holdings One plc and Rothschild;

         (c)      a supplemental trust deed dated 10 December 2001 between
                  National Grid Company, National Grid, National Grid Holdings
                  One plc and The Law Debenture Trust Corporation p.l.c.;

         (d)      a credit agreement dated 22 November 2001 between (1) National
                  Grid (as guarantor and borrower); (2) NGGF (as borrower); (3)
                  National Grid Holdings One plc (as guarantor and borrower);
                  (4) Dresdner Kleinwort Wasserstein Limited, J.P. Morgan plc,
                  ABN AMRO Bank N.V., Bank of America Securities, The Bank of
                  Tokyo-Mitsubishi Ltd, Barclays Capital, Bayerische Landesbank
                  Girozentrale London Branch, Citibank N.A., HSBC Investment
                  Bank plc and TD Bank Europe Limited; (5) HSBC Investment Bank
                  plc; (6) HSBC (USA) Inc.; and (7) certain banks and financial
                  institutions;

         (e)      a letter agreement dated 20 November 2001 between National
                  Grid, National Grid Company, National Grid Holdings One plc
                  and EIB;

         (f)      the trust deeds, subscription agreements and paying agency
                  agreements relating to the Euro 1,250,000,000 5.25 per cent.
                  guaranteed bonds due 2006 and the Euro 750,000,000 6.125 per
                  cent. guaranteed bonds due 2011 issued by NGGF and guaranteed
                  by National Grid and National Grid Holdings One plc, which
                  were summarised in the offering circular issued by NGGF on 20
                  August 2001;

         (g)      the trust deeds, subscription agreements and paying agency
                  agreements relating to the (pound) 200,000,000 3.806 per cent.
                  Retail Price Index-linked bonds due 2020, the (pound)
                  40,000,000 3.589 per cent. limited Retail Price Index-linked
                  bonds due 2030 and the (pound) 360,000,000 6.50 per cent.
                  bonds due 2028 issued by National Grid Company, which were
                  summarised in the offering circular issued by National Grid
                  Company on 23 July 2001;

         (h)      an asset purchase agreement dated as of 11 December 2000 and
                  made between Niagara Mohawk Power, Constellation Nuclear LLC
                  ("Constellation Nuclear") and Constellation Energy Group,
                  Inc., as guarantor of Constellation Nuclear;

         (i)      an asset purchase agreement dated as of 11 December 2000 and
                  made between Niagara Mohawk Power, Rochester Gas and Electric
                  Corporation, Central Hudson Gas and Electric Corporation, New
                  York State Electric and Gas Corporation, Constellation Nuclear
                  and Constellation Energy Group, Inc., as guarantor of
                  Constellation Nuclear; and

         (j)      the Niagara Mohawk Merger Agreement.

                                       228<PAGE>
                                                                   Exhibit 10.14

*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

CORIXA CORPORATION
1124 Columbia Street, Suite 200
Seattle WA 98104, USA
ATTENTION: STEVE GILLIS

RE:     CLARIFICATIONS SOUGHT IN CONNECTION WITH THE MULTI-FIELD VACCINE
        DISCOVERY COLLABORATION AND LICENSE AGREEMENT, ENTERED INTO SEPTEMBER 1,
        1998, BETWEEN CORIXA CORPORATION("CORIXA") AND SMITHKLINE BEECHAM PLC
        ("GSK") AS AMENDED (THE "AGREEMENT")

Dear Steve:

As we discussed at the Collaboration Steering Committee meeting held June 12,
2001, Corixa and GSK wish to confirm hereby their understanding regarding the
maintenance of GSK's exclusive rights in Fields with respect to which GSK begins
Clinical R&D and the definition of "Therapeutic Drug Monitoring" or "TDM".
Please note that capitalized terms not otherwise defined in this letter shall
have the meanings ascribed to them in the Agreement.

Following is our understanding of the terms and conditions under which GSK
maintains the exclusive rights and licenses in a particular Field where GSK
begins Clinical R&D with a particular Active Immune Response Product or Passive
Immune Transfer Product prior to the lapse of the Intended Clinical Delay:

1.      If GSK begins Clinical R&D with an Active Immune Response Product or
        Passive Immune Transfer Product containing at least one (1) [*] and/or
        [*] for use in the [*] Field, i.e. [*] in humans, subject to Corixa's
        right to terminate the Agreement as provided for in Section 17 thereof,
        GSK shall be deemed to have begun Clinical R&D in the [*] but not also
        in the [*] Field and all rights and licenses granted to GSK pursuant to
        Section 5 with respect to the [*] but not also with respect to the [*]
        Field shall be valid in accordance with the terms of the Agreement for
        so long as GSK is engaged in Clinical R&D, further clinical development
        or commercialisation of at least one (1) Active Immune Response Product
        or Passive Immune Transfer Product in the [*], as per the Agreement.

2.      For any field other than [*], if GSK begins Clinical R&D with an Active
        Immune Response Product or Passive Immune Transfer Product containing a
        Corixa Antigen and/or R&D Program Antigen, other than a [*], which has
        been discovered or identified within the framework of an R&D Program in
        a particular Field ("Field 1") and has been selected as a Viable
        Clinical Development Candidate for human clinical studies conducted in
        another Field ("Field 2"), subject to Corixa's right to terminate the
        Agreement as provided for in Section 17 thereof, GSK shall be deemed to
        have begun Clinical R&D in both Field 1 and Field 2 and the rights and
        licenses granted to GSK

--------
* Confidential treatment requested.

                                        1
<PAGE>

        pursuant to Section 5 with respect to both Fields shall be valid in
        accordance with the terms of the Agreement for so long as GSK is engaged
        in Clinical R&D, further clinical development or commercialisation of at
        least one (1) Active Immune Response Product or Passive Immune Transfer
        Product in Field 1 or in Field 2, as per the Agreement.

We agreed to clarify the definition of "Therapeutic Drug Monitoring" or "TDM"
contained in Section 1 (xxxxx) of the Agreement to read as follows :

3.      "Therapeutic Drug Monitoring" (or "TDM") shall mean the use of
        Antigen(s) solely for the purpose of [*] for an Active Immune Response
        Product and/or a Passive Immune Transfer Product that incorporates or is
        based on such Antigen(s), or for [*] such Active Immune Response Product
        and/or Passive Immune Transfer Product, as applicable, either during the
        [*] of such Active Immune Response Product and/or Passive Immune
        Transfer Product, as applicable, or following [*] thereof.

        For further clarification, a TDM Product can only be [*].

If Corixa agrees to the foregoing, please have the enclosed duplicate original
of this letter executed as indicated below and returned to my attention.

Best regards,

Jean Stephenne
Attorney-in-Fact
SMITHKLINE BEECHAM PLC

AGREED TO AND ACCEPTED BY :

CORIXA CORPORATION

--------------------------------------
Steven Gillis
Chairman and Chief Executive Officer

--------
* Confidential treatment requested.

                                        2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}]]